logo
Appendix 4C – Q3 FY25 Quarterly Cash Flow Report

Appendix 4C – Q3 FY25 Quarterly Cash Flow Report

Highlights
MELBOURNE, Australia and SAN FRANCISCO, April 30, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ('Alterity' or 'the Company'), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today released its Appendix 4C Quarterly Cash Flow Report and update on company activities for the quarter ending 31 March 2025 (Q3 FY25).
David Stamler, M.D., Chief Executive Officer of Alterity, commented, 'The third fiscal quarter of 2025 was one of our most successful periods to date for Alterity Therapeutics. The outstanding results from our ATH434 Phase 2 double-blind trial continue to demonstrate the tremendous potential for ATH434 as a disease modifying treatment for MSA and are resonating throughout the medical community. For individuals living with MSA, there is currently no approved therapy to help stabilize or improve their condition, and we believe that ATH434 may be able to change this paradigm.'
'During the quarter we also completed our open-label Phase 2 trial in patients with more advanced MSA. Data from this study are expected mid-year and will provide insights on the effects of ATH434 treatment in a population that faces severe challenges due to the advanced stage of their illness. We look forward to engaging with the U.S. Food and Drug Administration and European regulatory authorities as we seek to advance the development of ATH434 for individuals living with MSA,' concluded Dr Stamler.
Alterity's cash position on 31 March 2025 was A$17.96M with operating cash outflows for the quarter of A$0.73M. In accordance with ASX Listing Rule 4.7C, payments of A$80K made to related parties and their associates included in item 6.1 of the Appendix 4C incorporates directors' fees, consulting fees, remuneration and superannuation at commercial rates.
Operational Activities
ATH434–201: Randomized, Double-Blind, Placebo Controlled Phase 2 Clinical Trial in MSA
On 30 January 2025, Alterity announced the positive topline results led by robust clinical efficacy. Subsequent to the quarter end, on 10 April 2025, an oral presentation was delivered at the American Academy of Neurology (AAN) 2025 Annual Meeting that provided additional data from the trial. Overall, the study results support continued advancement of ATH434 for the treatment of MSA.
The ATH434-201 Phase 2 clinical trial is a randomized, double-blind, placebo-controlled investigation of ATH434 in patients with MSA. In addition to evaluating the efficacy of ATH434 and its impact on biomarkers, wearable sensors were employed to evaluate outpatient activity levels relevant to patients with MSA. The study enrolled 77 individuals with MSA who were randomly assigned to receive one of two dose levels of ATH434 or placebo. Participants received treatment for 12 months.
The clinical analysis included 71 patients who had at least one post-baseline assessment of the key clinical endpoint, the modified UMSARS1 I activities of daily living scale. On this endpoint, ATH434 demonstrated a clinically significant reduction in disease severity versus placebo, with a 48% relative treatment effect at the 50 mg dose (p=0.02)^ and a 30% relative treatment effect at the 75 mg dose (p=0.16) at 52 weeks. Additional efficacy assessments showed improvement consistent with the UMSARS I findings: the Clinical Global Impression of Severity Scale2 demonstrated improvement compared to placebo at both dose levels, with difference at 50 mg achieving nominal statistical significance (p=0.0088). On the Orthostatic Hypotension Symptom Assessment (a patient reported outcome), on average placebo patients worsened by approximately 6 points over 52 weeks whereas both ATH434 treatment groups improved over the same period (p=0.08 at 50 mg, p=0.14 at 75 mg). Increased activity in the outpatient setting was observed at both dose levels as compared to placebo as measured by wearable sensors, with clinically meaningful improvements in step count, bouts of walking, total walking time, and total standing time. ATH434 was well tolerated with similar adverse event rates compared to placebo and no serious adverse events attributed to ATH434. Regarding neuroimaging, ATH434 demonstrated target engagement by stabilizing or reducing iron at both dose levels compared to placebo in MSA affected brain regions. In addition, ATH434 demonstrated trends in reducing brain atrophy at both dose levels compared to placebo. Overall, the study results support continued advancement of ATH434 for the treatment of MSA.
ATH434–202: Open-label, Biomarker Phase 2 Clinical Trial in Advanced MSA
On 27 March 2025, Alterity announced that the last patient in the ATH434-202 Phase 2 trial completed the study. The ATH434-202 is an open label study designed to evaluate the safety, efficacy and target engagement of ATH434 in participants with advanced MSA. The 202 study gives Alterity the opportunity to evaluate the effects of ATH434 treatment in an MSA population more advanced than individuals enrolled in the ATH434-201 study. These individuals face severe challenges due to the stage of their illness. The data from this study will help Alterity guide the MSA development program given the differences between the 202 study and the double-blind trial. Alterity expects to report topline data from this study in mid-year 2025.
Corporate Activities
During the period, Alterity strengthened its balance sheet with a total of approximately A$15.0M raised in gross proceeds through financing transactions. Subsequent to the end of the quarter, an additional A$27.1M was raised upon completion of the second tranche of the two-tranche placement. During the period, Alterity was also granted a settlement in relation to the refund of $1.65M from the Australian Taxation Office under the Australian Government's Research and Development Tax Incentive (R&DTI) Scheme for eligible activities conducted during the financial year ending 30 June 2020.
The Company expects to use these funds to accelerate ATH434 regulatory and development activities and to continue research and discovery of novel compounds for additional indications such as Parkinson's disease.
About Alterity Therapeutics Limited
Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company is initially focused on developing disease modifying therapies in Parkinson's disease and related disorders. Alterity recently reported positive data for its lead asset, ATH434, in a Phase 2 clinical trial in participants with Multiple System Atrophy (MSA), a rare and rapidly progressive Parkinsonian disorder. ATH434 is also being evaluated in a Phase 2 clinical trial in advanced MSA. In addition, Alterity has a broad drug discovery platform generating patentable chemical compounds to treat the underlying pathology of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company's website at www.alteritytherapeutics.com.
References:
1 UMSARS: Unified Multiple System Atrophy Rating Scale
^ All p-values are uncorrected
2 Clinical Global Impression of Severity: a clinician assessment of the total picture of the subject including the impact of the illness on function and level of distress
Authorisation & Additional information
This announcement was authorized by David Stamler, CEO of Alterity Therapeutics Limited.
Investor and Media Contacts:
Australia
Millie Macdonald
Head of Investor Relations and Business Development
[email protected]
+61 3 9349 4906
Ana Luiza Harrop
[email protected]
+61 452 510 255
U.S.
Remy Bernarda
[email protected]
+1 (415) 203-6386
Forward Looking Statements
This press release contains 'forward-looking statements' within the meaning of section 27A of the Securities Act of 1933 and section21EoftheSecuritiesExchangeActof1934.TheCompanyhastriedtoidentifysuchforward-lookingstatementsbyuse of such words as 'expects,' 'intends,' 'hopes,' 'anticipates,' 'believes,' 'could,' 'may,' 'evidences' and 'estimates,' and other similar expressions, but these words are not the exclusive means of identifying suchstatements.
Importantfactorsthatcouldcauseactualresultstodiffermateriallyfromthoseindicatedbysuchforward-lookingstatements aredescribedinthesectionstitled'RiskFactors'intheCompany'sfilingswiththeSEC,includingitsmostrecentAnnualReport onForm20-FaswellasreportsonForm6-K,including,butnotlimitedtothefollowing:statementsrelatingtotheCompany's drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the Company'sdrugdevelopmentprogram,including,butnotlimitedto,ATH434,andanyotherstatementsthatarenothistorical facts.Suchstatementsinvolverisksanduncertainties,including,butnotlimitedto,thoserisksanduncertaintiesrelatingtothe difficultiesordelaysinfinancing,development,testing,regulatoryapproval,productionandmarketingoftheCompany'sdrug components,including,butnotlimitedto,ATH434,theabilityoftheCompanytoprocureadditionalfuturesourcesoffinancing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug compounds, including, but not limitedto,ATH434,thatcouldslowor prevent productscomingtomarket,the uncertaintyof obtaining patent protectionfortheCompany's intellectualpropertyortradesecrets, the uncertainty of successfully enforcing the Company's patent rights and the uncertainty of the Company freedom to operate.
Any forward-looking statement made by us in this press release is based only on information currently available to us and speaksonlyasofthedateonwhichitismade.Weundertakenoobligationtopubliclyupdateanyforward-lookingstatement, whetherwrittenororal,thatmaybemadefromtimetotime,whetherasaresultofnewinformation,futuredevelopmentsor otherwise.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Trimble Second Quarter Earnings Call and Webcast
Trimble Second Quarter Earnings Call and Webcast

Yahoo

timea few seconds ago

  • Yahoo

Trimble Second Quarter Earnings Call and Webcast

WESTMINSTER, Colo., July 24, 2025 /PRNewswire/ -- Trimble (Nasdaq: TRMB) will hold a conference call on Wednesday, August 6, 2025 at 8 a.m. ET to review its second quarter 2025 results. The call will be broadcast live on the web at Investors and participants who wish to dial into the call may do so by first registering at Upon registration, dial-in details will be sent via email to the registrant. About Trimble Trimble is a global technology company that connects the physical and digital worlds, transforming the ways work gets done. With relentless innovation in precise positioning, modeling and data analytics, Trimble enables essential industries including construction, geospatial and transportation. Whether it's helping customers build and maintain infrastructure, design and construct buildings, optimize global supply chains or map the world, Trimble is at the forefront, driving productivity and progress. For more information about Trimble (Nasdaq: TRMB), visit: FTRMB View original content to download multimedia: SOURCE Trimble

GFG Expands Aljo Gold System, Outlines Next Drill Program and Steps Up Regional Exploration
GFG Expands Aljo Gold System, Outlines Next Drill Program and Steps Up Regional Exploration

Yahoo

timea few seconds ago

  • Yahoo

GFG Expands Aljo Gold System, Outlines Next Drill Program and Steps Up Regional Exploration

SASKATOON, Saskatchewan, July 24, 2025 (GLOBE NEWSWIRE) -- GFG Resources Inc. (TSXV: GFG | OTCQB: GFGSF) ('GFG' or the 'Company') reports the final assay results from the 12-hole (2,600 metre) Phase 1 2025 drill program at the Aljo Gold Project ('Aljo'), located on the Company's Goldarm Property ('Goldarm') in the prolific Timmins Gold District of Ontario, Canada (See Figures 1 and 2). Drilling successfully extended high-grade gold mineralization in the Hangingwall ('HW') and Main Zones, confirmed broad mineralized envelopes in the Aljo West Zone, and led to the discovery of a new Footwall ('FW') gold zone characterized by strong alteration, veining and visible gold (See Table 1 and Figures 3 and 4). Located just north of the Porcupine-Destor Deformation Zone and surrounded by active mining and milling operations and infrastructure, the Aljo project remains a high-priority target for expansion and discovery. A follow-up 3,000 metre ('m') drill program is scheduled to begin in the coming weeks. Plans are currently being formalized to take an aggressive approach that will include significant regional geochemical and geophysical programs to develop and expand the target pipeline. Drill ready targets such as Carr and a 4-kilometre segment of the Pipestone Fault are expected to see drilling in the fourth quarter. Brian Skanderbeg, President and CEO of GFG stated, 'We are thrilled with the results from our H1 drill campaign at Aljo. We have not only expanded the Main and HW Zones with significant high-grade mineralization but have also made a discovery at depth in the FW3 Zone - an area previously untested. The near-surface extensions and growing structural complexity support the potential for a sizeable, high-grade gold system. With only ~30 holes completed across the system, our results underscore the upside of the property and the opportunity to build critical mass in a tier-one gold camp. We are equally excited to ramp up our exploration efforts across the Goldarm property, driven by our strong belief in the Pipestone Fault's potential to host high-grade, multi-million-ounce gold deposits, similar to the world-class systems along the Porcupine-Destor Deformation Zone. This is an area of significant untapped potential.' Drill Program Highlights High-grade gold intercepts from the HW, Main and FW zones, including: 6.62 grams of gold per tonne ('g/t Au') over 11.2 m including 7.24 g/t Au over 10.2 m in ALJ-24-020, up dip of ALJ-24-012 of 13.94 g/t Au over 7.1 m. 4.13 g/t Au over 5.2 m including 8.98 g/t Au over 2.2 m in ALJ-24-018. 1.74 g/t Au over 13.2 m including 24.2 g/t Au over 0.5 m in ALJ-24-017. 4.39 g/t Au over 3.4 m in ALJ-24-019 New Footwall discovery ('FW3'): Hosted in strongly altered basalt with porphyry dykes; assays include 7.26 g/t Au over 0.6 m and 4.20 g/t Au over 0.7 m (ALJ-24-019). Zones remain open in all directions. Validation of near-surface mineralization and western extensions: 4.24 g/t Au over 3.0 m including 12.0 g/t Au over 1.0 m in ALJ-24-021. 1.20 g/t Au over 11.4 m including 5.12 g/t Au over 1.5 m in ALJ-25-025. 2.37 g/t Au over 4.0 m and 2.62 g/t Au over 2.4 m in ALJ-25-027, both with visible gold and 85 m step-out from ALJ-23-004 of 3.65 g/t Au over 6.3 m, including 18.4 g/t Au over 1.1 m. Broadened mineralized footprint: Strike length of the Aljo system now exceeds 600 m. Continuity confirmed from surface to over 300 m vertical depth across multiple zones. Anders Carlson, Vice President Exploration of GFG added, 'With fewer than 30 holes drilled, we've already delivered some of the best results in the project's history. The discovery of FW3 and consistent high grades in near-surface zones underscore the scalability of the system. We believe Aljo holds potential for a multi-zonal gold system with significant room for resource development and growth.' Technical Summary The H1-2025 program was designed to follow up on high-grade intercepts, test depth and lateral extensions, and evaluate new targets to the northwest. The drilling intersected multiple mineralized vein systems: HW Zone: Broad, high-grade quartz-carbonate veining within mafic pillow breccias proximal to an ultramafic contact. Highlights include 6.62 g/t Au over 11.2 m (ALJ-24-020) and 4.39 g/t Au over 3.4 m (ALJ-24-019), typically with visible gold. Main Zone: Hosted in variolitic mafic volcanics with stacked vein sets in proximity to porphyry dyking. ALJ-25-027 returned 2.37 g/t Au over 4.0 m and 2.62 g/t Au over 2.4 m less than 60 metres from surface with significant visible gold. FW3 Zone: Hosted in altered amygdaloidal basalt with feldspar porphyry intrusions and sulphide-bearing quartz veining. ALJ-24-019 intersected a 45 m thick altered panel with assays up to 7.26 g/t Au and remains open. Notable step-out holes include: ALJ-25-023 extended the Aljo West Zone 85 m down-dip with 0.54 g/t Au over 20.4 m. ALJ-25-026, a 75 m step-out, intersected 0.31 g/t Au over 32.0 m and a high-grade interval of 8.56 g/t Au over 0.9 m. ALJ-25-028 tested a historical intercept and encountered a mineralized porphyry system with fuchsite-bearing pyroxenite. Next Steps GFG is preparing to initiate a 3,000 m follow-up drill program in the coming weeks. The program will focus on: Expanding the new FW3 and associated FW Zones both along strike and down-plunge. Testing further extensions of the HW and Main Zones. Advancing new targets in the Aljo West and Northwest Zones. In addition to the drill program, GFG is well underway with its summer surface exploration programs focused on all three of its Timmins properties. A particular focus will be placed along a 4-kilometre stretch of the Pipestone Fault, located in the central area of the Goldarm Property. The Pipestone Fault is a productive structural corridor that hosts multiple gold systems despite being relatively underexplored. A recent discovery by Onyx Gold Corp. of 3.4 g/t Au over 69.6 m, 1.8 g/t Au over 91.0 m and 2.2 g/t Au over 52.2 m underscore the potential for high-grade, large-scale mineral systems along the Pipestone Fault. Plans for this regional program will include an aggressive approach including geochemical, geophysical and both base-of-till sonic and diamond drilling. About the Aljo Gold Project The Aljo Gold Project lies within GFG's Goldarm Property, located in the Timmins Gold District of northeastern Ontario. The property is situated near the Porcupine-Destor Deformation Zone and includes historical underground workings. The project is proximal to regional mills and producers, offering excellent infrastructure and discovery potential in a tier-one jurisdiction. Table 1: Summary of 2025 Aljo Mine Project Assay Results (1) Hole ID From (m) To (m) Length (m) Au (g/t) Zone Visible Gold New ALJ-25-023 172.9 193.3 20.4 0.54 Northwest incl. 177.5 178.2 0.7 2.54 Northwest also incl. 185.0 186.5 1.5 1.87 Northwest ALJ-25-025 20.0 31.4 11.4 1.20 Main - West Ext incl. 20.0 21.5 1.5 5.12 Main - West Ext and 41.0 46.5 5.5 1.28 Main - West Ext and 169.0 169.7 0.7 2.97 Main - West Ext ALJ-25-026 18.0 19.0 1.0 1.23 Main - West Ext and 34.5 41.2 6.7 0.63 Main - West Ext and 87.6 119.5 32.0 0.31 Main - West Ext and 125.9 126.8 0.9 8.56 Main - West Ext ✓ ALJ-25-027 43.5 47.5 4.0 2.37 Main ✓ incl. 46.0 47.5 1.5 5.92 Main ✓ and 50.9 52.4 1.5 1.37 Main ✓ and 57.6 62.0 4.4 0.52 Main ✓ and 68.0 72.5 4.5 1.12 Main ✓ incl. 72.0 72.5 0.5 7.83 Main ✓ and 78.8 81.2 2.4 2.62 Main ✓ incl. 78.8 79.4 0.6 7.52 Main ✓ and 136.1 136.6 0.5 4.25 Main ✓ and 152.5 157.0 4.5 0.47 Main and 167.3 168.2 0.9 1.34 HW ALJ-25-028 123.2 124.2 1.0 1.10 North ALJ-24-017 45.8 59.0 13.2 1.74 HW ✓ incl. 45.8 46.3 0.5 24.20 HW ✓ also incl. 54.5 55.0 0.5 5.72 HW ✓ and 71.5 74.5 3.0 1.74 HW and 107.0 108.5 1.5 1.79 HW and 170.3 171.3 1.0 2.24 HW and 374.6 378.9 4.3 0.81 Main and 392.0 393.0 1.0 3.07 FW and 426.0 431.2 5.2 1.51 FW incl. 426.0 427.5 1.5 4.68 FW ALJ-24-018 115.5 120.7 5.2 4.13 HW ✓ incl. 118.5 120.7 2.2 8.98 HW ✓ and 183.2 186.0 2.8 2.16 HW incl. 184.2 185.2 1.0 3.84 HW and 214.1 227.8 13.8 0.43 Main and 272.9 274.3 1.4 2.26 Main incl. 273.4 274.3 0.9 3.33 Main and 327.2 328.7 1.4 5.90 Main ALJ-24-019 5.3 8.7 3.4 4.39 HW ✓ incl. 8.0 8.7 0.7 10.70 HW ✓ and 27.0 28.5 1.5 7.76 HW ✓ and 34.5 38.0 3.5 1.01 HW and 42.3 49.3 7.0 1.07 HW incl. 45.8 46.8 1.0 5.24 HW and 58.3 61.7 3.5 0.76 HW and 97.4 104.4 7.0 0.48 Main and 133.3 135.5 2.2 1.94 Main ✓ and 140.0 140.5 0.5 8.00 Main ✓ and 182.5 183.5 1.0 1.27 Main and 202.2 203.7 1.5 2.78 Main incl. 203.0 203.7 0.8 5.11 Main and 228.0 235.0 7.0 0.66 Main incl. 231.2 231.9 0.7 4.16 Main and 254.7 255.8 1.1 1.21 Main and 364.0 366.6 2.6 0.55 FW3 and 383.3 384.2 0.8 1.52 FW3 and 387.0 388.5 1.5 2.17 FW3 incl. 387.0 387.7 0.7 4.20 FW3 and 391.5 392.1 0.6 7.26 FW3 ALJ-24-020 49.3 49.8 0.5 32.70 HW ✓ and 70.7 81.9 11.2 6.62 HW ✓ incl. 71.7 81.9 10.2 7.24 HW ✓ and 109.5 111.0 1.5 1.92 HW and 129.5 133.3 3.8 2.67 HW ✓ incl. 132.2 132.7 0.5 16.40 HW ✓ and 137.5 142.0 4.5 0.85 HW and 167.0 168.0 1.0 4.92 HW ALJ-25-021 12.3 15.3 3.0 4.24 Main - West Ext ✓ incl. 13.3 14.3 1.0 12.00 Main - West Ext ✓ and 23.0 26.4 3.4 0.71 Main - West Ext and 178.3 186.0 7.7 0.51 Main - West Ext ALJ-25-022 15.2 16.5 1.3 4.38 Main - West Ext ✓ incl. 15.2 15.8 0.7 8.21 Main - West Ext ✓ and 43.3 46.8 3.5 0.71 Main - West Ext and 61.5 64.0 2.5 0.85 Main - West Ext ALJ-25-024 4.8 9.0 4.2 0.53 Northwest and 21.5 25.0 3.5 0.44 Northwest and 37.1 49.6 12.6 0.69 Northwest incl. 41.0 42.0 1.0 2.49 Northwest *Drill intercepts are presented using a 0.20 g/t Au cut-off and as drilled length with a minimum 1 gram-metre product. Composites include internal dilution of up to 3 m at grades less than 0.20 g/t Au. Included intervals are calculated using a 1 g/t cut-off at a minimum 1 gram-metre product unless otherwise stated. True width is estimated to be 30 to 90% drilled length. Figure 1: Regional Map of GFG Gold Projects in the Timmins Gold DistrictFigure 2: Goldarm Property Plan View MapFigure 3: Aljo Gold Project Plan View Map(1)Figure 4: Aljo Project Cross Section(1)About GFG Resources Inc. GFG is a North American precious metals exploration company focused on district scale gold projects in tier one mining jurisdictions. The Company operates three gold projects, each hosting large and highly prospective gold properties within the prolific gold district of Timmins, Ontario, Canada. The projects have similar geological settings that host most of the gold deposits found in the Timmins Gold Camp which have produced over 70 million ounces of gold. Brian Skanderbeg, President & CEOor Marc Lepage, Vice President, Business Development Phone: (306) 931-0930 Email: info@ Stay Connected with UsX (Twitter): GFGResourcesLinkedIn: (1) Drill intercepts are presented using a 0.2 g/t Au cut-off and as drilled length. Composites include internal dilution of up to 3 m at grades less than 0.2 g/t Au. Included intervals are calculated using a 1 g/t cut-off at a minimum 1 gram-metre product unless otherwise stated. True width is estimated to be 30 to 90% of drilled length. Sampling protocols, quality control and assurance measures and geochemical results related to historic drill core samples quoted in this news release have not been verified by the Qualified Person and therefore must be regarded as estimates. All scientific and technical information contained in this press release has been prepared under the supervision of Anders Carlson, and Vice President, Exploration of GFG, a qualified person within the meaning of National Instrument 43-101. Drill core samples are being analyzed for gold by Activation Laboratories Ltd. in Timmins, Ontario. Gold analysis consists of the preparation of a 500-gram pulp and an assay of a 50-gram aliquot by Pb collection fire assay with an Atomic Absorption Spectrometry finish (Package 1A2-50. Samples assaying above 5 ppm Au are routinely re-run using a gravimetric finish (Package 1A3-50). Selected samples are analysed by metallic screen method (Package 1A4) using a 100-mesh in order to better determine the size of gold grains in the system. Selected samples are also undergoing multi-element analysis for 59 other elements using a four-acid digestion and an ICP-MS finish (Package MA250) by Bureau Veritas Commodities Canada Ltd. in Vancouver, British Columbia. Quality control and assurance measures include the monitoring of results for inserted certified reference materials, coarse blanks and preparation duplicates of drill core. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. CAUTION REGARDING FORWARD-LOOKING INFORMATION All statements, other than statements of historical fact, contained in this news release constitute 'forward-looking information' within the meaning of applicable Canadian securities laws and 'forward-looking statements' within the meaning of the United States Private Securities Litigation Reform Act of 1995 (referred to herein as 'forward-looking statements'). Forward-looking statements include, but are not limited to, the Company's future exploration plans with respect to its property interests and the timing thereof, the prospective nature of the projects, future price of gold, success of exploration activities and metallurgical test work, permitting time lines, currency exchange rate fluctuations, requirements for additional capital, government regulation of exploration work, environmental risks, unanticipated reclamation expenses, title disputes or claims and limitations on insurance coverage. Generally, these forward-looking statements can be identified by the use of forward-looking terminology such as 'plans', 'expects' or 'does not expect', 'is expected', 'budget', 'scheduled', 'estimates', 'forecasts', 'intends', 'anticipates' or 'does not anticipate' or 'believes', or the negative connotation thereof or variations of such words and phrases or state that certain actions, events or results, 'may', 'could', 'would', 'will', 'might' or 'will be taken', 'occur' or 'be achieved' or the negative connotation thereof. All forward-looking statements are based on various assumptions, including, without limitation, the expectations and beliefs of management, the assumed long-term price of gold, that the Company will receive required permits and access to surface rights, that the Company can access financing, appropriate equipment and sufficient labour, and that the political environment within Canada will continue to support the development of mining projects. In addition, the similarity or proximity of other gold deposits to the Company's projects is not necessary indicative of the geological setting, alteration and mineralization of the Goldarm Property, the Pen Gold Project and the Dore Gold Project. Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of GFG to be materially different from those expressed or implied by such forward-looking statements, including but not limited to: actual results of current exploration activities; environmental risks; future prices of gold; operating risks; accidents, labour issues and other risks of the mining industry; availability of capital, delays in obtaining government approvals or financing; and other risks and uncertainties. These risks and uncertainties and the additional risks described in the Company's most recently filed annual and interim MD&A are not and should not be construed as being exhaustive. Although GFG has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. In addition, forward-looking statements are provided solely for the purpose of providing information about management's current expectations and plans and allowing investors and others to get a better understanding of our operating environment. Accordingly, readers should not place undue reliance on forward-looking statements. Forward-looking statements in this news release are made as of the date hereof and GFG assumes no obligation to update any forward-looking statements, except as required by applicable laws. Photos accompanying this announcement are available at: in to access your portfolio

Materialise Reports Second Quarter 2025 Results
Materialise Reports Second Quarter 2025 Results

Business Wire

time2 minutes ago

  • Business Wire

Materialise Reports Second Quarter 2025 Results

LEUVEN, Belgium--(BUSINESS WIRE)--Materialise NV (NASDAQ:MTLS), a leading provider of additive manufacturing and medical software and of sophisticated 3D printing services, today announced its financial results for the second quarter ended June 30, 2025. Highlights – Second Quarter 2025 Total consolidated revenue decreased 5.8% to 64,831 kEUR compared to the corresponding 2024 period; however at the same time our Materialise Medical segment showed a further 16.7% growth. Gross profit as a percentage of revenue for the second quarter of 2025 increased to 58.3%, compared to 57.0% for the corresponding 2024 period. Adjusted EBIT improved to 3,058 kEUR for the second quarter of 2025 from 646 kEUR for the first quarter of 2025, although it remained below the 3,872 kEUR of the corresponding 2024 period. Net result for the second quarter remained positive at 199 kEUR, or 0.0 EUR per diluted share, despite a significant impact from unfavorable exchange rate fluctuations. Driven by positive free cash flow during the first half of 2025, our reported net cash position increased by 2,025 kEUR to 63,045 kEUR compared to December 31, 2024. CEO Brigitte de Vet-Veithen commented, 'Our Materialise Medical segment once again demonstrated its resilience, growing by almost 17% compared to the same period of 2024. At the same time increasing geo-political uncertainty and sustained macro-economic headwinds negatively impacted revenues in our Materialise Manufacturing and Materialise Software segments, and therefore also our consolidated revenue in the second quarter of 2025. Despite revenue pressure we were able to materially improve our operational profitability in Q2 2025 compared to prior periods through structural and targeted cost control. Unfavorable effects from exchange rate fluctuations significantly impacted our quarterly financials, but we nevertheless again reported a positive net result.' Second Quarter 2025 Results Total revenue for the second quarter of 2025 decreased 5.8% to 64,831 kEUR from 68,797 kEUR for the second quarter of 2024. Adjusted EBIT was 3,058 kEUR for the second quarter of 2025 compared to 3,872 kEUR for the 2024 period. The Adjusted EBIT margin (Adjusted EBIT divided by total revenue) for the second quarter of 2025 was 4.7%, compared to 5.6% for the second quarter of 2024. Adjusted EBITDA for the second quarter of 2025 was 8,288 kEUR compared to 9,188 kEUR for the 2024 period. Revenue from our Materialise Medical segment increased 16.7% to 32,850 kEUR for the second quarter of 2025 compared to 28,141 kEUR for the same period in 2024. Segment Adjusted EBITDA amounted to 10,728 kEUR for the second quarter of 2025 compared to 8,199 kEUR, while the segment Adjusted EBITDA margin was 32.7% compared to 29.1% for the second quarter of 2024. Revenue from our Materialise Software segment decreased 12.1% to 9,872 kEUR for the second quarter of 2025 from 11,226 kEUR for the same quarter last year. Segment Adjusted EBITDA remained stable at 1,373 kEUR from 1,374 kEUR, while the segment Adjusted EBITDA margin was 13.9% compared to 12.2% for the corresponding prior-year period, reflecting the impact of strict cost control. Revenue from our Materialise Manufacturing segment decreased 24.9% to 22,109 kEUR for the second quarter of 2025 from 29,429 kEUR for the second quarter of 2024. Segment Adjusted EBITDA amounted to (807) kEUR compared to 2,416 kEUR for the same period in 2024, while the segment Adjusted EBITDA margin was (3.6)% compared to 8.2% for the second quarter of 2024. Gross profit was 37,778 kEUR for the second quarter of 2025 compared to 39,227 kEUR for the same period last year, while gross profit as a percentage of revenue increased to 58.3% compared to 57.0% for the second quarter of 2024. Research and development ('R&D'), sales and marketing ('S&M'), and general and administrative ('G&A') expenses decreased, in the aggregate, by 0.8% to 36,334 kEUR for the second quarter of 2025 from 36,631 kEUR for the second quarter of 2024. Net other operating income was 1,286 kEUR compared to 1,205 kEUR for the second quarter of 2024. Operating result amounted to 2,730 kEUR compared to 3,801 kEUR for the second quarter of 2024. Net financial result was (3,052) kEUR compared to 1,033 kEUR for the second quarter of 2024, reflecting highly unfavorable effects from unrealized exchange rate fluctuations. The second quarter of 2025 contained income tax benefits of 521 kEUR, compared to income tax expenses of (959) kEUR in the second quarter of 2024. As a result of the above, net profit for the second quarter of 2025 was 199 kEUR, compared to 3,875 kEUR for the same period in 2024. Total comprehensive income for the second quarter of 2025, which includes exchange differences on translation of foreign operations, was 823 kEUR compared to 3,093 kEUR for the corresponding 2024 period. At June 30, 2025, we report 116,712 kEUR cash and cash equivalents on our balance sheet compared to 102,304 kEUR at December 31, 2024. Gross debt amounted to 53,667 kEUR, compared to 41,284 kEUR at December 31, 2024. As a result, our reported net cash position was 63,045 kEUR, an increase of 2,025 kEUR compared to December 31, 2024. Cash flow from operating activities for the second quarter of 2025 was (27) kEUR compared to 8,400 kEUR for the same period in 2024. Total cash out from capital expenditures for the second quarter of 2025 amounted to 4,729 kEUR. Net shareholders' equity at June 30, 2025 was 249,488 kEUR compared to 248,578 kEUR at December 31, 2024. 2025 Guidance Mrs. de Vet-Veithen concluded, 'As we move through 2025 we see a risk that geo-political volatility and macro-economic uncertainty intensify and also impact the business climate for the remainder of this year. Unfavorable foreign exchange fluctuations might also add to the pressure on our revenue line and reported net result. We therefore believe it is prudent to slightly reduce our revenue guidance for the full fiscal year to a range of 265,000 to 280,000 kEUR. We remain convinced though that the fundamentals of our business are solid and resilient and believe that further structural cost efficiencies will allow us to safeguard operational profitability. Despite the slightly lower revenue outlook we are therefore reconfirming our Adjusted EBIT guidance of 6,000 kEUR to 10,000 kEUR for fiscal year 2025 in line with our earlier communications in February and April of this year.' Non-IFRS Measures Materialise uses EBIT, EBITDA, Adjusted EBIT and Adjusted EBITDA as supplemental financial measures of its financial performance. EBIT is calculated as net profit plus income taxes, financial expenses (less financial income) and shares of profit or loss in a joint venture. EBITDA is calculated as net profit plus income taxes, financial expenses (less financial income), shares of profit or loss in a joint venture and depreciation and amortization. Adjusted EBIT and Adjusted EBITDA are determined by adding to EBIT and EBITDA, respectively (i) share-based compensation expenses, (ii) acquisition or divestiture-related expenses of business combinations, (iii) impairments and revaluation of fair value due to business combinations and (iv) costs incurred in relation to corporate initiatives, restructurings or reorganizations that are of a non-recurring nature. Management believes these non-IFRS measures to be important measures as they exclude the effects of items which primarily reflect the impact of financing decisions and, in the case of EBITDA and Adjusted EBITDA, long term investment, rather than the performance of the company's day-to-day operations. The company also uses segment Adjusted EBITDA to evaluate the performance of its three business segments. As compared to net profit, these measures are limited in that they do not reflect the cash requirements necessary to service interest or principal payments on the company's indebtedness and, in the case of EBITDA and Adjusted EBITDA, these measures are further limited in that they do not reflect the periodic costs of certain capitalized tangible and intangible assets used in generating revenues in the company's business, or the changes associated with impairments. Management evaluates such items through other financial measures such as financial expenses, capital expenditures and cash flow provided by operating activities. The company believes that these measurements are useful to measure a company's ability to grow or as a valuation measurement. The company's calculation of EBIT, EBITDA, Adjusted EBIT and Adjusted EBITDA may not be comparable to similarly titled measures reported by other companies. EBIT, EBITDA, Adjusted EBIT and Adjusted EBITDA should not be considered as alternatives to net profit or any other performance measure derived in accordance with IFRS. The company's presentation of EBIT, EBITDA, Adjusted EBIT and Adjusted EBITDA should not be construed to imply that its future results will be unaffected by unusual or non-recurring items. Exchange Rate This document contains translations of certain euro amounts into U.S. dollars at specified rates solely for the convenience of readers. Unless otherwise noted, all translations from euros to U.S. dollars in this document were made at a rate of EUR 1.00 to USD 1.1720, the reference rate of the European Central Bank on June 30, 2025. Conference Call and Webcast Materialise will hold a conference call and simultaneous webcast to discuss its financial results for the second quarter of 2025 on Thursday, July 24, 2025, at 8:30 a.m. ET/2:30 p.m. CET. Company participants on the call will include Brigitte de Vet-Veithen, Chief Executive Officer and Koen Berges, Chief Financial Officer. A question-and-answer session will follow management's remarks. To access the call by phone, please click the link below at least 15 minutes prior to the scheduled start time and you will be provided with dial-in details. Participants can choose to dial in or receive a call to connect to Materialise's conference call. The conference call will also be broadcast live over the Internet with an accompanying slide presentation, which can be accessed on the company's website at The webcast of the conference call will be archived on the company's website for one year. About Materialise Materialise NV incorporates more than three decades of 3D printing experience into a range of software solutions and 3D printing services that empower sustainable 3D printing applications. Our open, secure, and innovative end-to-end solutions enable flexible industrial manufacturing and mass personalization in various industries — including healthcare, automotive, aerospace, eyewear, art and design, wearables, and consumer goods. Headquartered in Belgium and with branches worldwide, Materialise NV combines the largest group of software developers in the industry with one of the world's largest and most complete 3D printing facilities. For additional information, please visit: Cautionary Statement on Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, regarding, among other things, our intentions, beliefs, assumptions, projections, outlook, analyses or current expectations, plans, objectives, strategies and prospects, both financial and business, including statements concerning, among other things, our estimates for the current fiscal year's revenue and Adjusted EBIT, our results of operations, cash needs, capital expenditures, expenses, financial condition, liquidity, prospects, growth and strategies (including how our business, results of operations and financial condition could be impacted by the current armed geopolitical conflicts around the world and governmental responses thereto, inflation, increased labor, energy and materials costs), policy changes resulting from the U.S. presidential administration, changes in tariffs and trade restrictions, and the trends and competition that may affect the markets, industry or us. Such statements are subject to known and unknown uncertainties and risks. When used in this press release, the words 'estimate,' 'expect,' 'anticipate,' 'project,' 'plan,' 'intend,' 'believe,' 'forecast,' 'will,' 'may,' 'could,' 'might,' 'aim,' 'should,' and variations of such words or similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon the expectations of management under current assumptions at the time of this press release. These expectations, beliefs and projections are expressed in good faith and the company believes there is a reasonable basis for them. However, the company cannot offer any assurance that our expectations, beliefs and projections will actually be achieved. By their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics and industry change, and depend on economic circumstances that may or may not occur in the future or may occur on longer or shorter timelines than anticipated. We caution you that forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control. All of the forward-looking statements are subject to risks and uncertainties that may cause the company's actual results to differ materially from our expectations, including risk factors described in the company's most recent annual report on Form 20-F filed with the U.S. Securities and Exchange Commission. There are a number of risks and uncertainties that could cause the company's actual results to differ materially from the forward-looking statements contained in this press release. The company is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise, unless it has obligations under the federal securities laws to update and disclose material developments related to previously disclosed information. Consolidated income statements (Unaudited) for the three months ended June 30, for the six months ended June 30, In '000 2025 2025 2024 2025 2024 U.S.$ € € € € Revenue 75,982 64,831 68,797 131,210 132,434 Cost of Sales (31,707) (27,053) (29,570) (56,708) (57,270) Gross Profit 44,276 37,778 39,227 74,502 75,164 Gross profit as % of revenue 58.3% 58.3% 57.0% 56.8% 56.8% Research and development expenses (13,032) (11,120) (11,090) (22,534) (21,322) Sales and marketing expenses (18,132) (15,471) (15,636) (30,542) (30,234) General and administrative expenses (11,420) (9,744) (9,905) (19,769) (19,214) Net other operating income (expenses) 1,508 1,286 1,205 1,646 1,994 Operating (loss) profit 3,200 2,730 3,801 3,303 6,387 Financial expenses (4,733) (4,039) (1,441) (6,811) (2,239) Financial income 1,157 987 2,474 2,884 4,783 (Loss) profit before taxes (376) (322) 4,834 (624) 8,930 Income Taxes 610 521 (959) 287 (1,469) Net (loss) profit for the period 234 199 3,875 (337) 7,461 Net (loss) profit attributable to: The owners of the parent 233 199 3,882 (336) 7,474 Non-controlling interest - - (7) (2) (13) Earning per share attributable to owners of the parent Basic 0.00 0.00 0.07 (0.01) 0.13 Diluted 0.00 0.00 0.07 (0.01) 0.13 Weighted average basic shares outstanding 59,067 59,067 59,067 59,067 59,067 Weighted average diluted shares outstanding 59,067 59,067 59,067 59,067 59,077 Expand Consolidated statements of comprehensive income (Unaudited) for the three months ended June 30, for the six months ended June 30, In 000€ 2025 2025 2024 2025 2024 U.S.$ € € € € Net profit (loss) for the period 234 199 3,875 (337) 7,461 Other comprehensive income Recycling Exchange difference on translation of foreign operations 731 624 (783) 1,129 (1,056) Non-recycling Fair value adjustments through OCI - Equity instruments - - - - - Other comprehensive income (loss), net of taxes 731 624 (783) 1,129 (1,056) Total comprehensive income (loss) for the year, net of taxes 964 823 3,093 792 6,406 Total comprehensive income (loss) attributable to: The owners of the parent 958 817 3,100 785 6,419 Non-controlling interests 6 6 (7) 7 (14) Expand Consolidated statement of financial position (Unaudited) As of June 30, As of December 31, In 000€ 2025 2024 Assets Non-current assets Goodwill 43,249 43,391 Intangible assets 27,751 29,973 Property, plant & equipment 111,225 111,331 Right-of-Use assets 6,920 7,719 Deferred tax assets 3,761 3,523 Investments in convertible loans 4,118 3,994 Other non-current assets 5,707 5,893 Total non-current assets 202,729 205,823 Current assets Inventories 14,678 16,992 Trade receivables 49,564 53,052 Other current assets 16,197 18,166 Cash and cash equivalents 116,712 102,304 Assets held for sale 4,504 - Total current assets 201,656 190,513 Total assets 404,385 396,336 Expand As of June 30, As of December 31, In 000€ 2025 2024 Equity and liabilities Equity Share capital 4,487 4,487 Share premium 233,895 233,895 Retained earnings and other reserves 11,106 10,196 Equity attributable to the owners of the parent 249,488 248,578 Non-controlling interest (78) (86) Total equity 249,410 248,492 Non-current liabilities Loans & borrowings 38,388 23,175 Lease liabilities 4,641 5,112 Deferred tax liabilities 2,923 3,202 Deferred income 15,343 13,268 Other non-current liabilities 326 910 Total non-current liabilities 61,621 45,666 Current liabilities Loans & borrowings 8,151 10,383 Lease liabilities 2,487 2,614 Trade payables 20,091 23,348 Tax payables 560 1,432 Deferred income 45,070 45,998 Other current liabilities 16,049 18,403 Liabilities held for sale 944 - Total current liabilities 93,354 102,178 Total equity and liabilities 404,385 396,336 Expand Consolidated statement of cash flows (Unaudited) for the six months ended June 30, In 000€ 2025 2024 Operating activities Net (loss) profit for the period (337) 7,461 Non-cash and operational adjustments 14,087 10,203 Depreciation of property plant & equipment 7,448 7,539 Amortization of intangible assets 3,210 3,204 Share-based payment expense 117 142 Loss (gain) on disposal of intangible assets and property, plant & equipment (21) (77) Government grants (101) - Movement in provisions (366) 191 Movement reserve for bad debt and slow moving inventory 271 272 Financial income (2,876) (4,762) Financial expense 6,770 2,241 Impact of foreign currencies (70) (10) (Deferred) income taxes (295) 1,462 Working capital adjustments (4,684) (574) Decrease (increase) in trade receivables and other receivables 2,093 3,134 Decrease (increase) in inventories and contracts in progress (500) (1,029) Increase (decrease) in deferred revenue (264) (1,768) Increase (decrease) in trade payables and other payables (6,014) (911) Income tax paid & Interest received 620 1,280 Net cash flow from operating activities 9,686 18,370 Expand for the six months ended June 30, In 000€ 2025 2024 Investing activities Purchase of property, plant & equipment (5,617) (10,475) Purchase of intangible assets (944) (814) Proceeds from the sale of property, plant & equipment & intangible assets (net) 233 185 Capital government grants received 2,640 - Net cash flow used in investing activities (3,688) (11,104) Financing activities Proceeds from loans & borrowings 20,000 - Repayment of loans & borrowings (6,860) (6,841) Repayment of leases (1,544) (1,517) Capital increase - - Interest paid (621) (800) Other financial income (expense) (1,300) 169 Net cash flow from (used in) financing activities 9,676 (8,989) Net increase/(decrease) of cash & cash equivalents 15,673 (1,723) Cash & Cash equivalents at the beginning of the year 102,304 127,573 Exchange rate differences on cash & cash equivalents (913) (358) Cash & cash equivalents at end of the period 117,064 125,492 Expand Reconciliation of Net Profit (Loss) to EBITDA and Adjusted EBITDA (Unaudited) for the three months ended June 30, for the six months ended June 30, In 000€ 2025 2024 2025 2024 Net profit (loss) for the period 199 3,875 (337) 7,461 Income taxes (521) 959 (287) 1,469 Financial expenses 4,039 1,441 6,811 2,239 Financial income (987) (2,474) (2,884) (4,783) Depreciation and amortization 5,230 5,316 10,731 10,754 EBITDA 7,960 9,117 14,034 17,141 Share-based compensation expense (1) 45 71 117 142 Restructuring and corporate initiatives (2) 283 - 283 - Adjusted EBITDA 8,288 9,188 14,434 17,283 (1) Share-based compensation expense represents the cost of equity-settled and share-based payments to employees. (2) Non-recurring costs related to corporate initiatives, restructurings or reorganizations. Expand Reconciliation of Net Profit (Loss) to EBIT and Adjusted EBIT (Unaudited) for the three months ended June 30, for the six months ended June 30, In 000€ 2025 2024 2025 2024 Net profit (loss) for the period 199 3,875 (337) 7,461 Income taxes (521) 959 (287) 1,469 Financial expenses 4,039 1,441 6,811 2,239 Financial income (987) (2,474) (2,884) (4,783) EBIT 2,730 3,801 3,303 6,387 Share-based compensation expense (1) 45 71 117 142 Restructuring and corporate initiatives (2) 283 - 283 - Adjusted EBIT 3,058 3,872 3,703 6,529 (1) Share-based compensation expense represents the cost of equity-settled and share-based payments to employees. (2) Non-recurring costs related to corporate initiatives, restructurings or reorganizations. Expand Segment P&L (Unaudited) In 000€ Materialise Medical Materialise Software Materialise Manufacturing Total segments Unallocated (1) Consolidated For the three months ended June 30, 2025 Revenues 32,850 9,872 22,109 64,831 (0) 64,831 Segment (adj) EBITDA 10,728 1,373 (807) 11,294 (3,005) 8,288 Segment (adj) EBITDA % 32.7% 13.9% -3.6% 17.4% 12.8% For the three months ended June 30, 2024 Revenues 28,141 11,226 29,429 68,797 0 68,797 Segment (adj) EBITDA 8,199 1,374 2,416 11,990 (2,802) 9,188 Segment (adj) EBITDA % 29.1% 12.2% 8.2% 17.4% 13.4% In 000€ Materialise Medical Materialise Software Materialise Manufacturing Total segments Unallocated (1) Consolidated For the six months ended June 30, 2025 Revenues 63,928 19,647 47,635 131,210 (0) 131,210 Segment (adj) EBITDA 19,775 1,971 (1,185) 20,561 (6,127) 14,434 Segment (adj) EBITDA % 30.9% 10.0% -2.5% 15.7% 11.0% For the six months ended June 30, 2024 Revenues 54,324 21,665 56,445 132,434 0 132,434 Segment (adj) EBITDA 16,120 2,464 3,947 22,531 (5,248) 17,283 Segment (adj) EBITDA % 29.7% 11.4% 7.0% 17.0% 13.1% Expand (1) Unallocated segment adjusted EBITDA consists of corporate research and development and corporate other operating income (expense), and the added share-based compensation expenses, acquisition or divestiture-related expenses of business combinations, impairments and revaluation of fair value of business combinations and non-recurring costs related to corporate initiatives, restructurings and reorganizations that are included in Adjusted EBITDA and that are not allocated to the reporting segments. Expand Reconciliation of Net Profit (Loss) to Segment adjusted EBITDA (Unaudited) for the three months ended June 30, for the six months ended June 30, In 000€ 2025 2024 2025 2024 Net profit (loss) for the period 199 3,875 (337) 7,461 Income taxes (521) 959 (287) 1,469 Financial cost 4,039 1,441 6,811 2,239 Financial income (987) (2,474) (2,884) (4,783) Operating (loss) profit 2,730 3,801 3,303 6,387 Depreciation and amortization 5,230 5,316 10,731 10,754 Corporate research and development 1,070 955 2,100 1,763 Corporate headquarter costs 2,895 2,601 5,747 5,083 Other operating income (expense) (810) (682) (1,498) (1,456) Segment restructuring and reorganization 178 - 178 - Segment adjusted EBITDA 11,294 11,990 20,561 22,531 Expand

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store